<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565836</url>
  </required_header>
  <id_info>
    <org_study_id>15092404</org_study_id>
    <nct_id>NCT02565836</nct_id>
  </id_info>
  <brief_title>Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate for Warfarin-associated Major Bleed</brief_title>
  <official_title>Reversal of Warfarin-associated Major Hemorrhage: a Multicenter, Retrospective Cohort Study of Fixed-dose Activated (FEIBA VH) Versus Variable-dose Inactivated (Kcentra) Prothrombin Complex Concentrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Advocate Health Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess a fixed-dose regimen of activated prothrombin complex concentrate
      (FEIBA VH, Baxter) versus the variable, manufacturer recommended, dose regimen of inactivated
      prothrombin complex concentrate (Kcentra, CSL Behring) for reversal of warfarin-associated
      major hemorrhage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Warfarin, a vitamin K antagonist (VKA), is the most frequently prescribed oral anticoagulant.
      Warfarin-associated major hemorrhage occurs at a rate of 1.7% to 3.4% in routine clinical
      practice and warrants rapid reversal of anticoagulation by correcting supratherapeutic
      international normalized ratio (INR) values.

      Warfarin inhibits synthesis of vitamin K dependent coagulation factors II, VII, IX, and X,
      and strategies for reversal of warfarin-associated coagulopathy are aimed at restoring
      deficient factors. Four-factor prothrombin complex concentrates (PCCs) contain the
      coagulation factors which warfarin inhibits and are an attractive option for rapid reversal
      due to ease of reconstitution and no requirement for blood-type matching.

      Manufacturer dosing recommendations exist for PCCs based on patient weight, baseline INR, and
      target INR, but studies have suggested fixed dosing strategies in an effort to determine the
      most efficacious dose for VKA-reversal while sparing adverse events. These studies have also
      utilized different PCC formulations, with some studies utilizing 4-factor activated PCC
      (aPCC), which denotes product containment of factor VII in an activated state.

      In the United States, product availability is limited to a single 4-factor aPCC (FEIBA VH,
      Baxter) indicated for hemophilia patients with inhibitors and a single 4-factor inactivated
      PCC (Kcentra, CSL Behring) approved for VKA-reversal. Various institutions choose to utilize
      off-label fixed dosing strategies of 4-factor aPCC in an effort to administer the lowest
      possible dose to reverse VKAs, while others utilize manufacturer recommended dosing of
      4-factor inactivated PCC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">September 30, 2016</completion_date>
  <primary_completion_date type="Actual">September 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of INR less than or equal to 1.5</measure>
    <time_frame>60 minutes</time_frame>
    <description>The number of patients achieving a goal INR of less than or equal to 1.5 within 60 minutes following administration of 4-factor fixed-dose aPCC (FEIBA VH) versus variable-dose inactivated PCC (Kcentra) for reversal of warfarin-associated major hemorrhage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of mortality or thrombotic events</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of mortality, deep vein thrombosis, pulmonary embolism, myocardial infarction, and ischemic cerebrovascular events within 30 days following administration of 4-factor fixed-dose aPCC (FEIBA VH) or variable-dose inactivated PCC (Kcentra) for reversal of warfarin-associated major hemorrhage.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">342</enrollment>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>fixed-dose aPCC</arm_group_label>
    <description>Patients receiving fixed-dose activated prothrombin complex concentrate (FEIBA VH) for reversal of warfarin-associated major hemorrhage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>variable-dose PCC</arm_group_label>
    <description>Patients receiving vairable-dose inactivated prothrombin complex concentrate (Kcentra) for reversal of warfarin-associated major hemorrhage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fixed-dose activated prothrombin complex concentrate</intervention_name>
    <description>FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.
Check INR after infusion and may repeat dose if INR still elevated</description>
    <arm_group_label>fixed-dose aPCC</arm_group_label>
    <other_name>FEIBA</other_name>
    <other_name>FEIBA VH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>variable-dose inactivated prothrombin complex concentrate</intervention_name>
    <description>Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.
Check INR after infusion and may repeat dose if INR still elevated.</description>
    <arm_group_label>variable-dose PCC</arm_group_label>
    <other_name>Kcentra</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients administered a prothrombin complex concentrate as part of routine care for INR
        normalization due to a major bleed will be assessed for inclusion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-treatment INR lab value greater than 1.5

          -  Receipt of treatment with a 4-factor PCC for INR normalization due to
             warfarin-associated major hemorrhage

        Exclusion Criteria:

          -  Patients treated with a PCC for an urgent invasive procedure without active hemorrhage

          -  Patients treated with PCC not taking a VKA

          -  Unavailable pre- or post-treatment INR lab values

          -  Pregnant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary D Peksa, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Mokszycki, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advocate Christ Medical Center</affiliation>
  </overall_official>
  <reference>
    <citation>Junagade P, Grace R, Gover P. Fixed dose prothrombin complex concentrate for the reversal of oral anticoagulation therapy. Hematology. 2007 Oct;12(5):439-40.</citation>
    <PMID>17852462</PMID>
  </reference>
  <reference>
    <citation>WÃ³jcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med. 2009 Nov 26;2(4):217-25. doi: 10.1007/s12245-009-0125-8.</citation>
    <PMID>20436891</PMID>
  </reference>
  <reference>
    <citation>Khorsand N, Veeger NJ, van Hest RM, Ypma PF, Heidt J, Meijer K. An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. Haematologica. 2012 Oct;97(10):1501-6. doi: 10.3324/haematol.2012.063701. Epub 2012 Apr 4.</citation>
    <PMID>22491734</PMID>
  </reference>
  <reference>
    <citation>Stewart WS, Pettit H. Experiences with an activated 4-factor prothrombin complex concentrate (FEIBA) for reversal of warfarin-related bleeding. Am J Emerg Med. 2013 Aug;31(8):1251-4. doi: 10.1016/j.ajem.2013.05.008. Epub 2013 Jun 10.</citation>
    <PMID>23763937</PMID>
  </reference>
  <reference>
    <citation>Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013 Sep 10;128(11):1234-43. doi: 10.1161/CIRCULATIONAHA.113.002283. Epub 2013 Aug 9.</citation>
    <PMID>23935011</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin K 1</keyword>
  <keyword>prothrombin complex concentrates</keyword>
  <keyword>warfarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Thrombin</mesh_term>
    <mesh_term>Feiba</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

